anastrozole + pazopanib

Anastrozole + pazopanib is a combination of two small molecule drugs used experimentally in oncology, particularly in hormone receptor-positive cancers. Anastrozole is a non-steroidal aromatase inhibitor that reduces estrogen production by inhibiting the aromatase enzyme, thereby decreasing estrogen-driven tumor growth. Pazopanib is a second-generation multitargeted tyrosine kinase inhibitor that blocks vascular endothelial growth factor receptors (VEGFR-1, -2, -3), platelet-derived growth factor receptors (PDGFR-alpha and PDGFR-beta), and c-kit, disrupting angiogenesis and tumor blood supply. This combination has been studied in clinical trials for advanced or metastatic hormone receptor-positive breast cancer and certain sarcomas[4][2]. The rationale for combining these agents lies in targeting both hormonal pathways (anastrozole) and angiogenic signaling pathways (pazopanib) to enhance antitumor efficacy.

Other names

anastrozole and pazopanibpazopanib plus anastrozole